These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 2071611

  • 21. A novel mutation in the fibrinogen Aα chain (Gly13Arg, fibrinogen Nanning) causes congenital dysfibrinogenemia associated with defective peptide A release.
    Yan J, Luo M, Cheng P, Liao L, Deng X, Deng D, Lin F.
    Int J Hematol; 2017 Apr; 105(4):506-514. PubMed ID: 27933517
    [Abstract] [Full Text] [Related]

  • 22. Polymerization defect of fibrinogen Baltimore III due to a gamma Asn308----Ile mutation.
    Bantia S, Bell WR, Dang CV.
    Blood; 1990 Apr 15; 75(8):1659-63. PubMed ID: 2328317
    [Abstract] [Full Text] [Related]

  • 23. Fibrinogen Milano XII: a dysfunctional variant containing 2 amino acid substitutions, Aalpha R16C and gamma G165R.
    Bolliger-Stucki B, Lord ST, Furlan M.
    Blood; 2001 Jul 15; 98(2):351-7. PubMed ID: 11435303
    [Abstract] [Full Text] [Related]

  • 24. Fibrinogen residue γAla341 is necessary for calcium binding and 'A-a' interactions.
    Park R, Ping L, Song J, Hong SY, Choi TY, Choi JR, Gorkun OV, Lord ST.
    Thromb Haemost; 2012 May 15; 107(5):875-83. PubMed ID: 22437918
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of fibrin polymerization by fragment d is affected by calcium, Gly-Pro-Arg and Gly-His-Arg.
    Furlan M, Rupp C, Beck EA.
    Biochim Biophys Acta; 1983 Jan 12; 742(1):25-32. PubMed ID: 6824684
    [Abstract] [Full Text] [Related]

  • 26. Fibrinopeptide A release is necessary for effective B:b interactions in polymerisation of variant fibrinogens with impaired A:a interactions.
    Soya K, Terasawa F, Okumura N.
    Thromb Haemost; 2013 Feb 12; 109(2):221-8. PubMed ID: 23238100
    [Abstract] [Full Text] [Related]

  • 27. Characterization of an abnormal fibrinogen Osaka V with the replacement of gamma-arginine 375 by glycine. The lack of high affinity calcium binding to D-domains and the lack of protective effect of calcium on fibrinolysis.
    Yoshida N, Hirata H, Morigami Y, Imaoka S, Matsuda M, Yamazumi K, Asakura S.
    J Biol Chem; 1992 Feb 05; 267(4):2753-9. PubMed ID: 1733971
    [Abstract] [Full Text] [Related]

  • 28. Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of B beta 68 Ala----Thr.
    Koopman J, Haverkate F, Lord ST, Grimbergen J, Mannucci PM.
    J Clin Invest; 1992 Jul 05; 90(1):238-44. PubMed ID: 1634610
    [Abstract] [Full Text] [Related]

  • 29. Fibrinogen Lima. A new dysfibrinogenaemia with a high-molecular-weight alpha-chain and effective polymerization.
    Arocha-Piñango CL, Rodriguez S, Nagy H, Perez Requejo JL.
    Blood Coagul Fibrinolysis; 1990 Oct 05; 1(4-5):561-5. PubMed ID: 2133234
    [Abstract] [Full Text] [Related]

  • 30. The role of fibrinogen D domain intermolecular association sites in the polymerization of fibrin and fibrinogen Tokyo II (gamma 275 Arg-->Cys).
    Mosesson MW, Siebenlist KR, DiOrio JP, Matsuda M, Hainfeld JF, Wall JS.
    J Clin Invest; 1995 Aug 05; 96(2):1053-8. PubMed ID: 7635941
    [Abstract] [Full Text] [Related]

  • 31. Fibrinogen Haifa: fibrinogen variant with absence of protective effect of calcium on plasmin degradation of gamma chains.
    Soria J, Soria C, Samama M, Tabori S, Kehl M, Henschen A, Nieuwenhuizen W, Rimon A, Tatarski I.
    Thromb Haemost; 1987 Jun 03; 57(3):310-3. PubMed ID: 2958955
    [Abstract] [Full Text] [Related]

  • 32. Fibrinogen Kyoto II, a new congenitally abnormal molecule, characterized by the replacement of A alpha proline-18 by leucine.
    Yoshida N, Okuma M, Hirata H, Matsuda M, Yamazumi K, Asakura S.
    Blood; 1991 Jul 01; 78(1):149-53. PubMed ID: 2070049
    [Abstract] [Full Text] [Related]

  • 33. An engineered fibrinogen variant AαQ328,366P does not polymerise normally, but retains the ability to form α cross-links.
    Park R, Ping L, Song J, Seo JY, Choi TY, Choi JR, Gorkun OV, Lord ST.
    Thromb Haemost; 2013 Feb 01; 109(2):199-206. PubMed ID: 23224113
    [Abstract] [Full Text] [Related]

  • 34. Recombinant γT305A fibrinogen indicates severely impaired fibrin polymerization due to the aberrant function of hole 'A' and calcium binding sites.
    Ikeda M, Kobayashi T, Arai S, Mukai S, Takezawa Y, Terasawa F, Okumura N.
    Thromb Res; 2014 Aug 01; 134(2):518-25. PubMed ID: 24968960
    [Abstract] [Full Text] [Related]

  • 35. Fibrinogen Philadelphia, a hypodysfibrinogenemia characterized by abnormal polymerization and fibrinogen hypercatabolism due to gamma S378P mutation.
    Keller MA, Martinez J, Baradet TC, Nagaswami C, Chernysh IN, Borowski MK, Surrey S, Weisel JW.
    Blood; 2005 Apr 15; 105(8):3162-8. PubMed ID: 15632207
    [Abstract] [Full Text] [Related]

  • 36. Fibrinogen Mahdia: A congenitally abnormal fibrinogen characterized by defective fibrin polymerization.
    Amri Y, Jouini H, Becheur M, Dabboubi R, Mahjoub B, Messaoud T, Sfar MT, Casini A, de Moerloose P, Toumi NEH.
    Haemophilia; 2017 Jul 15; 23(4):e340-e347. PubMed ID: 28594476
    [Abstract] [Full Text] [Related]

  • 37. Characterization of fibrinogen Milano I: amino acid exchange gamma 330 Asp----Val impairs fibrin polymerization.
    Reber P, Furlan M, Rupp C, Kehl M, Henschen A, Mannucci PM, Beck EA.
    Blood; 1986 Jun 15; 67(6):1751-6. PubMed ID: 3708159
    [Abstract] [Full Text] [Related]

  • 38. Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids A alpha 461-610 (Lys 461 AAA-->stop TAA).
    Koopman J, Haverkate F, Grimbergen J, Egbring R, Lord ST.
    Blood; 1992 Oct 15; 80(8):1972-9. PubMed ID: 1391954
    [Abstract] [Full Text] [Related]

  • 39. Fibrinogen Oviedo I. A new Spanish dysfibrinogenaemia.
    Fernández FJ, Rodríguez Pinto C, Páramo J, Cuesta B, Collado M, Rocha E.
    Blood Coagul Fibrinolysis; 1990 Oct 15; 1(4-5):571-5. PubMed ID: 2133236
    [Abstract] [Full Text] [Related]

  • 40. Fibrinogen Guarenas I: partial characterization of a new dysfibrinogenemia with an altered rate of fibrinopeptide release and an impaired polymerization.
    Lundberg UG, Rodriguez S, Marchi R, Ruiz-Saez A, Arocha-Piñango CL.
    Thromb Res; 1995 Apr 15; 78(2):95-106. PubMed ID: 7482436
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.